Abstract
Background
Cryoablation has garnered significant interest as a treatment for solid tumors including breast cancer for both its local effects and potential in stimulating an antitumor immune response. We sought to examine the impact that variances in technique might have on the immune response and examine the mechanism by which cryoablation may stimulate an antitumor immune response.
Materials and Methods
Balb/c mice with established 4T1 mammary carcinomas were treated by cryoablation at either a high rate of freeze or low rate of freeze, or by surgical excision, after spontaneous metastases occurred. Tumor-draining lymph nodes (TDLN) were excised at 1 week for EliSPOT assay and immunophenotyping. Mice were followed after treatment for enumeration of pulmonary metastases and survival.
Results
Compared with surgical excision, cryoablation using a high freeze rate resulted in a significant increase in tumor-specific T cells in the TDLN, a reduction in pulmonary metastases, and improved survival. However, cryoablation using a low freeze rate resulted in an increase in regulatory T cells, a significant increase in pulmonary metastases, and decreased survival.
Conclusions
Cryoablation of breast cancer in mice can generate a tumor-specific immune response that can eradicate systemic micrometastases and improve outcome compared with surgical excision; however, the technique used to freeze the tissue may alter the immune response from stimulatory to suppressive.
Similar content being viewed by others
References
Gursel E, Roberts M, Veenema RJ. Regression of prostatic cancer following sequential cryotherapy to the prostate. J Urol. 1972;108:928–32.
Soanes WA, Ablin RJ, Gonder MJ. Remission of metatatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol. 1970;104:154–9.
Tramoyeres Cases A, Sanchez-Cuenca J, Tramoyeres Celma A, Beaumud G. A la criocirugia transperineal en al tratamiento del cancer prostatico. Arch Esp Urol. 1976;29:119–42.
Tanaka S. Cryosurgical treatment of advanced breast cancer. Skin Cancer. 1995;10:9–18.
Suzuki Y. Cryosurgical treatment of advanced breast cancer and cryoimmunological responses. Skin Cancer. 1995;10:19–26.
Tanaka S. Immunological aspects of cryosurgery in general surgery. Cryobiology. 1982;19:247–62.
Horan AH. Sequential cryotherapy for prostatic carcinoma: does it palliate the bone pain? Conn Med. 1975;39:81–3.
Ulschmid G, Kolb E, Largiader F. Cryosurgery of pulmonary metastases. Cryobiology. 1979;16:171–8.
Ablin RJ, Soanes WA, Gonder MJ. Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate. Cryobiology. 1971;8:271–9.
Neel HBd, Ketcham AS, Hammond WG. Experimental evaluation of in situ oncocide for primary tumor therapy: Comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation. Laryngoscope. 1973;83:376–87.
Bagley DH, Faraci RP, Marrone JC, Beazley RM. Lymphocyte mediated cytotoxicity after cryosurgery of a murine sarcoma. J Surg Res. 1974;17:404–6.
Blackwood CE, Cooper IS. Response of experimental tumor systems to cryosurgery. Cryobiology. 1972;9:508–15.
Hayakawa K, Yamashita T, Suzuki K, Tomita K, Hosokawa M, Kodama T, et al. Comparative immunological studies in rats following cryosurgery and surgical excision of 3-methylcholantrene-induced primary autochthousous tumors. Gann. 1982;73:462–9.
Yamashita T, Hayakawa K, Hosokawa M, Kodama T, Inoue N, Tomita K, et al. Enhanced tumor metastases in rats following cryosurgery of primary tumor. Gann. 1982;73:222–8.
Shibata T, Suzuki K, Yamashita T, Takeichi N, Mark M, Hosokawa M, et al. Immunological analysis of enhanced spontaneous metastasis in WKA rats following cryosurgery. Anticancer Res. 1998;18:2483–6.
Shibata T, Yamashita T, Suzuki K, Takeichi N, Micallef M, Hosokawa M, et al. Enhancement of experimental pulmonary metastasis and inhibition of subcutaneously transplanted tumor growth following cryosurgery. Anticancer Res. 1998;18:4443–8.
Hanawa S. An experimental study on the induction of anti-tumor immunological activity after cryosurgery for liver carcinoma, and the effect of concomitant immunotherapy with OK432. J Jpn Surg Soc. 1993;94:57–65.
Miya K, Saji S, Morita T, Niwa H, Sakata K. Experimental study on mechanism of absorption of cryonecrotized tumor antigens. Cryobiology. 1987;24:135–9.
Misao A, Sakata K, Saji S, Kuneida T. Late appearance of resistance to tumor rechallenge following cryosurgery: a study in an experimental mammary tumor of the rat. Cryobiology. 1981;18:386–9.
Miha K, Saji S, Morita T, Niwa H, Takao H, Kida H, et al. Immunological response of regional lymph nodes after tumor cryosurgery: experimental study in rats. Cryobiology. 1986;23:290–5.
Urano M, Tanaka C, Sugiyama T, Miya K, Saji S. Antitumor effects of residual tumor after cryoablation: the combined effect of residual tumor and a protein-bound polysaccharaide on multiple liver metastases in a murine model. Cryobiology. 2003;46:238–45.
Shibata T, Yamashita T, Suzuki K, Takeichi N, Micallef M, Hosokawa M, et al. Enhancement of experimental pulmonary metastaseis and inhibition of subcutaneously transplanted tumor growth following cryosurgery. Anticancer Res. 1998;18:4443–8.
Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JL, Chang AE. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005;90:97–104.
Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. In: John E. Coligen, editor. Current protocols in immunology, 2001; Chapter 20 (Unit 20.2).
Schultz J, Heinzerling L, Pavlovic J, Moelling K. Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. Cancer Gene Ther. 2000;7:1557–65.
Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.
Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8:271–80.
Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63:655–66.
Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol. 2001;167:2887–94.
Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195:99–111.
Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2002;276:10229–33.
Skoberne M, Beignon AS, Bhardwaj N. Danger signals: a time and space continuum. Trends Mol Med. 2004;10:251–7.
Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965–75.
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2 and PAF. J Clin Invest. 1998;101:890–8.
Peng Y, Martin DA, Kenkel J, Zhang K, Ogden CA, Elkon KB. Innate and adaptive immune response to apoptotic cells. J Autoimmun. 2007;29:303–9.
Viorritto ICB, Nikolov NP, Siegel RM. Autoimmunity versus tolerance: can dying cells tip the balance? Clin Immunol. 2007;122:125–34.
Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med. 2002;196:1079–90.
Huang FP, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T-cell areas of mesenteric lymph nodes. J Exp Med. 2000;191:435–44.
Stuart LM, Lucas M, Simpson C, Lamb J, Savill J, Lacy-Hulbert A. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J Immunol. 2002;168:1627–35.
Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med. 2002;196:1091–7.
Rock KL, Hearn A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol. 2005;26:231–46.
Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer. 2003;103:205–11.
Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Grégoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res. 1999;59:3329–32.
Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Röbe J, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T-cells and activate NK and gammadelta T cells. Cancer Res. 2002;62:2347–52.
Jenne L, Arrighi JF, Jonuleit H, Saurat JH, Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. 2000;60:4446–52.
Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P. Cutting edge: by-stander apoptosis triggers dendritic cells maturation and antigen-presenting function. J Immunol. 1998;161:4467–71.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sabel, M.S., Su, G., Griffith, K.A. et al. Rate of Freeze Alters the Immunologic Response After Cryoablation of Breast Cancer. Ann Surg Oncol 17, 1187–1193 (2010). https://doi.org/10.1245/s10434-009-0846-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-009-0846-1